CONMED (CNMD)
(Delayed Data from NYSE)
$75.24 USD
-0.11 (-0.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $75.25 +0.01 (0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
CNMD 75.24 -0.11(-0.15%)
Will CNMD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CNMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNMD
New Strong Sell Stocks for September 17th
New Strong Sell Stocks for September 11th
CNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Conmed (CNMD) Up 13.2% Since Last Earnings Report?
Do Options Traders Know Something About CONMED (CNMD) Stock We Don't?
New Strong Sell Stocks for August 19th
Other News for CNMD
Conmed Announces Executive Departure and New Interim Controller
Conmed Performance Analysis: Hold Rating Justified Amid Supply Chain Resolutions and Gross Margin Adjustments
CONMED Corporation to Participate in a Virtual Fireside Chat at the CL King Best Ideas Conference
How To YieldBoost CNMD To 15.5% Using Options
Baird Q2 2024 Small/Mid Cap Growth Equity Fund Commentary